基蛋生物(603387) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥244,148,446.89, a decrease of 24.08% compared to ¥321,582,715.19 in the same period last year[4] - Net profit attributable to shareholders was ¥64,307,429.35, down 25.24% from ¥86,013,453.60 year-on-year[4] - The basic earnings per share decreased by 23.53% to ¥0.13 from ¥0.17 in the previous year[4] - Net profit for Q1 2025 was ¥62,303,411.24, a decline of 28.8% from ¥87,436,875.95 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.13, compared to ¥0.17 in Q1 2024[20] Cash Flow - The net cash flow from operating activities was ¥48,853,750.34, reflecting a decline of 27.21% compared to ¥67,114,506.07 in the same period last year[4] - Cash inflow from operating activities in Q1 2025 was ¥268,090,284.53, down 30.5% from ¥385,853,460.11 in Q1 2024[22] - Cash paid for purchasing goods and services in Q1 2025 was ¥34,212,792.59, a decrease of 64.6% from ¥96,495,187.57 in Q1 2024[22] - Net cash flow from operating activities was $48.85 million, down from $67.11 million, representing a decrease of approximately 27.3%[23] - The total cash and cash equivalents at the end of the period decreased to $274.59 million from $417.29 million, a decline of about 34.2%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,722,968,542.60, a slight increase of 0.42% from ¥3,707,374,587.49 at the end of the previous year[5] - Total liabilities as of the end of the reporting period were ¥945,912,792.10, down from ¥986,419,351.12 at the end of the previous period[17] - Total equity increased to ¥2,777,055,750.50 from ¥2,720,955,236.37 in the previous period[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,747[9] - The largest shareholder, Su Enben, holds 39.77% of the shares, totaling 201,670,295 shares[9] - Shareholders' equity attributable to shareholders increased by 2.50% to ¥2,684,361,465.12 from ¥2,618,960,854.01 at the end of the previous year[5] Operational Highlights - The company installed over 110 units of the MAGICL6000 and nearly 100 units of the MAGICL6000i in Q1 2025, contributing to growth in the chemiluminescence segment[12] - The Metis6000 fully automated immunoassay production line saw nearly 20 units installed in Q1 2025, with expectations for further growth as market coverage expands[12] - The GN7000/GN7120 fully automated nucleic acid amplification analyzers had over 30 units installed in Q1 2025, with over 70% of installations in secondary and higher-level hospitals[12] Cost Management - The company is focusing on enhancing cost control and improving operational efficiency across its business segments[11] - Total operating costs for Q1 2025 were ¥168,580,188.57, down 23.6% from ¥220,695,492.33 in Q1 2024[18] Investment Activities - Cash inflow from investment activities totaled $150.08 million, compared to $80.93 million, an increase of about 85.5%[23] - Cash outflow from investment activities was $294.03 million, up from $181.35 million, indicating a rise of approximately 62.1%[23] - The net cash flow from investment activities was negative at -$143.95 million, worsening from -$100.42 million[23] Financial Adjustments - The company reported a financial expense of -¥5,922,203.74 in Q1 2025, an improvement from -¥7,500,129.58 in Q1 2024[19] - The company recorded a fair value gain of ¥3,089,177.27 in Q1 2025, compared to a gain of ¥1,342,865.38 in Q1 2024[19] - The impact of exchange rate changes on cash and cash equivalents was a negative $85,746.95, contrasting with a positive impact of $410,246.62 previously[23] Future Outlook - The company aims to expand its market presence while leveraging its R&D capabilities in the IVD product line[11] - The company will not apply new accounting standards starting from 2025[24]